Pharmacy · Independent exam preparation
BCIDP Infectious Diseases Pharmacy: Clinical Decisions and Practice Guide Study Guide
Practise resistance-based treatment, diagnostic interpretation, exposure monitoring, prevention, and stewardship decisions for the BPS infectious diseases pharmacy examination.
By CertMedbry · Updated 29 October 2026
Choose active therapy, interpret infection diagnostics, identify treatment failure, and build safer antimicrobial systems. This guide connects pathogen biology with patient assessment, pharmacotherapy, monitoring, prevention, and stewardship. Its 60 concepts selectively sample the three official domains; the BPS examination content outline defines the full scope, including topics beyond this guide. The accompanying questions and flashcards are independent learning materials.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which examination and certification pathway does this guide address?
This guide addresses initial BPS Infectious Diseases Pharmacy specialty certification, leading to the BCIDP designation. The examination name and credential name describe the same certification program. Recertification requirements are a separate pathway and are not the organizing framework for these materials.
Infectious Diseases Pharmacy · BCIDP Examination Specifications — Effective October 2025
How many questions are scored, and how long is the examination?
The applicable specifications state 150 items: 125 scored and 25 unscored. Administration time is 3 hours 45 minutes. The unscored items contribute to the total examination length.
Which blueprint applies, and how are the domains weighted?
The ECO was created in October 2024 and applies to administrations from October 1, 2025 onward. It was verified as current on October 11, 2026. Domain weights are Pathophysiology and Epidemiology of Infections 18%, Therapeutics and Patient Management 60%, and Professional Practice 22%. This selective guide contains 9, 39, and 12 concepts in those domains respectively. The questions and flashcards each contain 4, 13, and 3. These sample allocations do not reproduce the official weights; the complete outline remains the study framework.
Examination Content Outlines · BCIDP Examination Specifications — Effective October 2025
How is the examination delivered, and how does navigation work?
BPS examinations are computer delivered. Navigation is forward-only: candidates answer items in sequence, cannot skip items, and cannot revisit or change an answer after confirming it and moving forward. Most items have four answer options. The Candidate’s Guide also describes other formats across some specialties; this does not establish a BCIDP-specific inventory of formats or an adaptivity classification. The questions here are independent four-option, single-best-answer exercises.
Do practice experience and residency routes lead to different examinations?
The specifications describe alternative eligibility routes involving qualifying practice experience, PGY1 residency plus experience, or PGY2 infectious diseases residency. These are eligibility routes to the same specialty certification examination. Graduation and active pharmacist licensure or registration requirements also apply. BPS recognizes qualifying education and licensure in the United States or another jurisdiction, subject to its requirements.
How should recent guidelines and jurisdictional differences be handled?
The 2026 Candidate’s Guide advises using current specifications and recognizes that examination assembly can lag practice changes; its suggested guidance window is approximately 6–12 months before administration when expectations are uncertain. This does not establish a fixed clinical cutoff. Clinical examples here use attributed U.S. CDC, NIH, IDSA, FDA, and AHRQ sources; local availability and jurisdictional requirements can differ.
BCIDP is BPS specialty certification for pharmacists with advanced infectious diseases knowledge and experience. This guide addresses the Infectious Diseases Pharmacy specialty certification examination that awards the Board-Certified Infectious Diseases Pharmacist designation.
Outline used: BPS BCIDP Examination Specifications, ECO created October 2024, effective for administrations from October 1, 2025 onward; verified as current on October 11, 2026. The workbook label names the credential, Board-Certified Infectious Diseases Pharmacist, awarded through the Infectious Diseases Pharmacy specialty certification examination. The assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Pathophysiology and Epidemiology of Infections18%
1.How does ESBL production change the meaning of a susceptible result?
Extended-spectrum beta-lactamases hydrolyze many penicillins, cephalosporins, and aztreonam. A laboratory susceptibility result must therefore be interpreted alongside the organism, resistance mechanism, infection site, and clinical evidence. For invasive ESBL-producing Enterobacterales infections, IDSA favors carbapenems rather than assuming that apparent piperacillin-tazobactam or cefepime susceptibility establishes equivalent effectiveness. The discriminating clue is an invasive infection caused by an ESBL producer, particularly bloodstream infection, rather than uncomplicated lower urinary tract disease.
Apply it
An adult has ESBL-producing Escherichia coli bacteremia from an abdominal source. Although piperacillin-tazobactam is reported susceptible, recommend a carbapenem and drainage of the collection, then reassess oral options after stability and source control.
Common pitfall: Choosing solely from the susceptible column ignores mechanism-specific clinical evidence. Conversely, a preference for carbapenems in invasive disease should not automatically dictate every uncomplicated cystitis regimen.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
2.What distinguishes Pneumocystis pneumonia from ordinary bacterial pneumonia?
Pneumocystis jirovecii is a fungus that causes pneumonia primarily when host defenses are impaired. HIV with substantial immune suppression, transplantation, and immunosuppressive treatment are important contexts. Progressive dyspnea, nonproductive cough, hypoxemia, and diffuse pulmonary abnormalities should raise suspicion, although none establishes the diagnosis alone. Organism classification does not predict susceptibility to routine antifungals: trimethoprim-sulfamethoxazole is preferred treatment. Recognizing the host and syndrome prevents anchoring on routine bacterial pneumonia.
Apply it
A patient with untreated HIV develops several weeks of exertional dyspnea, dry cough, and diffuse bilateral infiltrates. Include Pneumocystis in the diagnostic assessment and evaluate oxygenation rather than treating the presentation as routine bacterial pneumonia alone.
Common pitfall: Calling Pneumocystis a fungus does not justify an echinocandin as standard treatment. Host risk and pulmonary findings guide suspicion, but microbiologic assessment remains important.
Pneumocystis Pneumonia Basics · NIH: Pneumocystis Pneumonia — Brief View
3.Why can Strongyloides infection become severe decades after exposure?
Strongyloides stercoralis can maintain infection through autoinfection: larvae develop into infective forms within the host and penetrate intestinal mucosa or perianal skin. This cycle permits persistence long after exposure ends. Corticosteroids can precipitate accelerated autoinfection, hyperinfection, or dissemination. Gastrointestinal and pulmonary deterioration after immunosuppression, especially with remote residence in an endemic region, is a discriminating pattern. Absence of eosinophilia does not reliably exclude severe infection, particularly during corticosteroid treatment.
Apply it
A transplant candidate previously lived in an endemic region and is about to receive substantial corticosteroid therapy. Flag remote exposure as clinically relevant and arrange Strongyloides assessment before immunosuppression when feasible, rather than dismissing exposure because it occurred decades earlier.
Common pitfall: Ascaris also has a pulmonary migration phase, but it does not explain the same sustained internal autoinfection cycle. Remote travel alone does not make Strongyloides risk disappear.
CDC DPDx: Strongyloidiasis · CDC: Clinical Overview of Strongyloides · CDC DPDx: Ascariasis
4.When does a Candida auris result represent colonization?
Candida auris can colonize skin and other noninvasive sites without causing clinical infection. A positive screening swab therefore identifies a transmission concern rather than an automatic indication for antifungal treatment. CDC does not recommend treating asymptomatic colonization or detection at noninvasive sites without signs of infection. In contrast, recovery from blood with a compatible illness requires evaluation and treatment. The key distinction is the relationship between specimen site, clinical findings, and evidence of invasive disease.
Apply it
A clinically stable rehabilitation patient has a positive C. auris screening swab but no infectious symptoms. Maintain appropriate infection prevention measures and communication during transfer; do not prescribe an echinocandin solely to eradicate screening positivity.
Common pitfall: Withholding antifungal treatment for colonization does not mean the result can be ignored. Transmission precautions and transfer communication remain necessary despite the absence of invasive infection.
5.Which bacterial pathogens complicate severe influenza?
Influenza and bacterial pneumonia can coexist. CDC identifies Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus, including MRSA, as important causes of secondary bacterial pneumonia in severe influenza. Deterioration during antiviral treatment therefore does not establish antiviral resistance. Acute lung injury, inflammatory damage, and bacterial complications remain competing explanations. Recognizing these organisms broadens the etiologic assessment beyond the initial viral diagnosis without assuming that every influenza infection has a bacterial component.
Apply it
A patient hospitalized with influenza develops worsening pulmonary disease and a respiratory specimen growing S. aureus. Assess the specimen quality, imaging, severity, and clinical course for bacterial pneumonia rather than attributing deterioration automatically to oseltamivir resistance.
Common pitfall: A positive influenza test does not exclude bacterial coinfection. Conversely, influenza alone does not prove that antibacterial treatment is necessary.
6.What does a positive C. difficile toxin-gene test establish?
C. difficile causes disease through toxin production, especially the actions of toxins A and B. Nucleic acid amplification detects targeted toxin genes, which establishes the presence of a potentially toxigenic organism rather than proving that it causes the patient's symptoms. Colonized patients may test positive. Pathogenic toxin-A-negative, toxin-B-positive strains also exist, so requiring both toxins would be incorrect. Compatible diarrhea and appropriate specimen selection are essential for interpreting a positive molecular result.
Apply it
A hospitalized patient receives a laxative and has one loose stool; a molecular test is positive. Reassess whether clinically significant unexplained diarrhea is present and whether testing was appropriate before labeling the patient as having symptomatic C. difficile infection.
Common pitfall: A sensitive molecular assay does not distinguish colonization from symptomatic disease by itself. Requiring toxin A in every pathogenic strain creates a separate diagnostic error.
C. diff: Facts for Clinicians · Class II Special Controls Guideline Document: Toxin Gene Amplification Assays for the Detection of Clostridium difficile
7.How do KPC and metallo-beta-lactamases differ therapeutically?
KPC is a serine carbapenemase, whereas NDM and other metallo-beta-lactamases use zinc-dependent hydrolysis. This mechanistic difference determines which beta-lactamase inhibitors can restore activity. Agents active against KPC cannot be assumed active against NDM. Metallo-beta-lactamases do not hydrolyze aztreonam, but accompanying enzymes may; combining aztreonam with avibactam protection addresses that problem. A carbapenem-resistant phenotype alone is therefore less informative than the identified carbapenemase when selecting a targeted regimen.
Apply it
Two Klebsiella pneumoniae bloodstream isolates are carbapenem resistant, but one produces KPC and the other NDM. Request mechanism-informed treatment selection rather than assigning the same newer beta-lactam combination to both isolates based only on their shared resistance category.
Common pitfall: Avibactam inhibits important serine beta-lactamases but does not directly inhibit metallo-beta-lactamases. Ceftazidime-avibactam alone should not be assumed to cover an NDM producer.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
9.How does BCG vaccination affect tuberculosis testing?
Interferon-gamma release assays measure immune responses to selected Mycobacterium tuberculosis antigens and are not made positive by BCG vaccination. CDC therefore prefers TB blood testing for BCG-vaccinated people when age and clinical circumstances permit. Tuberculin skin testing can be affected by BCG and other factors. Neither test distinguishes latent infection from active disease. A positive result requires clinical evaluation, while concerning symptoms or significant immune suppression can warrant further investigation despite a negative result.
Apply it
A BCG-vaccinated adult requires TB infection screening before immunosuppressive therapy. Select an IGRA and plan additional evaluation if positive; explain that the blood test avoids BCG-related interference but does not independently diagnose or exclude active tuberculosis.
Common pitfall: Attributing a positive IGRA to childhood BCG vaccination is incorrect. Equally, a negative immune-based test cannot safely overrule a convincing clinical picture of tuberculosis disease.
10.Why can an infected intravascular catheter sustain candidemia?
Candida can form biofilms on intravascular devices, creating a persistent reservoir that systemic treatment may not reliably eliminate while the device remains in place. Continued positive blood cultures can therefore reflect inadequate source control rather than simply an insufficient antifungal dose. IDSA recommends early catheter removal in nonneutropenic candidemia when the catheter is the presumed source and removal is safe. The decision is individualized because not every candidemia episode originates from a catheter.
Apply it
A nonneutropenic patient remains candidemic while receiving an active echinocandin, and the central line is the likely source. Discuss prompt safe removal and repeat blood cultures rather than responding only by escalating antifungal exposure without addressing the device.
Common pitfall: Device removal should be guided by source assessment and safety. Persistent cultures require broader evaluation as well; a catheter is plausible but not the only possible reservoir.
IDSA Clinical Practice Guideline for the Management of Candidiasis
Therapeutics and Patient Management60%
8.Why must susceptibility be interpreted at the infection site?
Susceptibility testing describes organism-drug activity under standardized conditions, but clinical success also requires adequate exposure at the infected site. Drugs that concentrate in urine may be useful for bladder infection while failing to provide reliable renal parenchymal or bloodstream exposure. Nitrofurantoin and oral fosfomycin should not be selected for pyelonephritis merely because an isolate appears susceptible. Distinguish lower urinary symptoms from fever, flank pain, bacteremia, or other evidence of infection beyond the bladder.
Apply it
A patient with ESBL E. coli has fever, flank pain, and positive blood cultures. Reject nitrofurantoin despite a susceptible urine result and choose a regimen with appropriate systemic and renal tissue activity, guided by susceptibility and clinical severity.
Common pitfall: A urinary isolate does not mean infection is confined to urine. High urinary concentrations cannot compensate for inadequate drug exposure in renal tissue or blood.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
11.How do HBV status and pending resistance results affect initial HIV regimen selection?
For people without prior long-acting cabotegravir PrEP exposure, NIH recommends initial options including bictegravir/tenofovir alafenamide/emtricitabine or dolutegravir plus tenofovir alafenamide or tenofovir disoproxil fumarate with emtricitabine or lamivudine. Dolutegravir/lamivudine requires additional selection: it is unsuitable for rapid initiation before reverse-transcriptase genotype results or with unknown HBV status. With HBV coinfection, lamivudine alone is inadequate HBV treatment; a tenofovir-containing backbone provides an appropriate HBV-active approach when usable. Prior cabotegravir PrEP requires assessment for integrase resistance before selecting an INSTI regimen.
Apply it
A newly diagnosed adult without prior cabotegravir exposure needs rapid ART, but genotype and HBV results are pending. Assess a recommended three-drug option such as bictegravir/tenofovir alafenamide/emtricitabine, including renal suitability and interactions, rather than starting dolutegravir/lamivudine before its selection criteria can be established.
Common pitfall: Convenient two-drug therapy does not eliminate baseline assessment. Pending HBV and resistance results materially change whether dolutegravir/lamivudine is appropriate.
12.What HBV pattern supports vaccine-derived immunity?
The HBV triple panel combines hepatitis B surface antigen, antibody to surface antigen, and total antibody to core antigen. Vaccine-derived immunity typically produces anti-HBs without anti-HBc because the vaccine contains surface antigen rather than the viral core. HBsAg negativity argues against current detectable surface antigenemia. Interpret the pattern with vaccination history and the clinical context; an isolated quantitative antibody result should not replace the full assessment of infection history and immune status.
Apply it
An adult with documented vaccination has negative HBsAg, positive anti-HBs, and negative total anti-HBc. Explain that the pattern supports vaccine-derived immunity and does not indicate a prior natural infection or current hepatitis B infection in this context.
Common pitfall: Anti-HBs and anti-HBc are not interchangeable markers. Vaccine response does not ordinarily produce core antibody, while surface antibody alone should not be mistaken for current infection.
13.How is resolved hepatitis B distinguished from vaccination?
Resolved natural HBV infection typically produces negative HBsAg with positive anti-HBs and total anti-HBc. Core antibody provides the clue that natural infection occurred. This history remains relevant before immunosuppression because viral reactivation can occur even after surface antigen becomes negative. Assessment should connect the serologic pattern to the planned immunosuppressive exposure and appropriate reactivation prevention or monitoring, rather than labeling every anti-HBs-positive patient as having vaccine-only immunity.
Apply it
Before a patient's immunosuppressive treatment, testing shows negative HBsAg and positive anti-HBs plus total anti-HBc. Document resolved natural infection and ensure a reactivation-risk assessment instead of closing the review with the statement that the patient is simply vaccinated.
Common pitfall: Negative HBsAg does not erase prior infection or all reactivation risk. Positive anti-HBs cannot by itself establish that immunity resulted from vaccination rather than natural infection.
14.Why is isolated hepatitis B core antibody ambiguous?
Isolated total anti-HBc means HBsAg and anti-HBs are negative while core antibody is positive. Possible explanations include remote resolved infection with waning surface antibody, a false-positive result, occult infection, or a window-period pattern in an appropriate acute illness. It is therefore not a complete diagnosis. Exposure history, symptoms, immune status, and additional testing such as IgM anti-HBc or HBV DNA help distinguish these possibilities and determine the practical management decision.
Apply it
A patient being assessed before immunosuppression has isolated total anti-HBc. Review prior results and risk factors, and arrange targeted follow-up rather than declaring vaccine immunity. The planned therapy makes clarification of possible prior or occult infection particularly consequential.
Common pitfall: Treating isolated core antibody as a single definitive state ignores several biologically different possibilities. Total anti-HBc alone also cannot distinguish acute infection from remote exposure.
15.What evaluation follows a positive tuberculosis infection test?
A positive IGRA or tuberculin skin test indicates an immune response consistent with TB infection, but does not separate latent infection from TB disease. Evaluation includes history, symptom assessment, examination, and chest imaging, with bacteriologic testing when disease is suspected. Latent infection is diagnosed only after active disease has been excluded. This distinction changes treatment selection and infection prevention: a latent-infection regimen is not an adequate substitute for treatment of active tuberculosis.
Apply it
An asymptomatic employee has a positive IGRA during screening. Arrange evaluation including chest imaging before selecting preventive treatment. If cough, weight loss, or abnormal imaging emerges, pursue assessment for TB disease rather than automatically starting a latent-infection regimen.
Common pitfall: Starting preventive monotherapy before excluding active disease risks inadequate treatment. A positive immune test identifies infection risk but does not determine disease activity or infectiousness by itself.
16.How is vancomycin exposure estimated in a simplified model?
For a simplified linear, steady-state intravenous model, AUC over 24 hours equals total daily dose divided by vancomycin clearance. This calculation links drug input with elimination rather than using a trough as a direct exposure substitute. For serious MRSA infections, the consensus target is an AUC/MIC of 400–600 when MIC is assumed to be 1 mg/L. Clinical estimation requires suitable concentration data or validated Bayesian methods and reassessment when patient kinetics change.
Apply it
Assume stable linear kinetics, a total intravenous daily dose of 2,000 mg, and clearance of 4 L/hour. Calculate AUC24 as 2,000 divided by 4, or 500 mg·hour/L; at MIC 1 mg/L, the numerical AUC/MIC is 500.
Common pitfall: A convenient calculation does not validate its assumptions in unstable renal function. The serious-MRSA exposure target should not be presented as equally established for every organism and syndrome.
Consensus Guideline for Therapeutic Monitoring of Vancomycin
17.Why does changing renal function undermine a stable dosing estimate?
Vancomycin exposure depends strongly on clearance, which may change rapidly during critical illness, recovery, or acute kidney injury. A regimen estimated to achieve an appropriate AUC under yesterday's conditions may cause accumulation when clearance falls. The consensus guideline emphasizes monitoring in patients with unstable renal function and those at increased nephrotoxicity risk. Interpret concentrations with dose timing, renal trajectory, and clinical status; apparent numerical precision does not make an outdated pharmacokinetic estimate reliable.
Apply it
A patient's vancomycin AUC was acceptable before new oliguria and rising creatinine developed. Reassess administration and exposure promptly, obtain appropriately timed monitoring, and evaluate renal injury rather than continuing unchanged because the previous estimate was within the target range.
Common pitfall: A historical AUC is not a permanent property of the prescribed dose. Repeating the same regimen without considering changing clearance can turn adequate treatment into excessive exposure.
Consensus Guideline for Therapeutic Monitoring of Vancomycin
18.How should barriers to antiretroviral adherence be assessed?
Adherence problems may reflect medication access, unstable housing, transportation, mental health, substance use, adverse effects, regimen complexity, or competing priorities. NIH recommends an individualized, nonjudgmental assessment rather than assuming lack of motivation. Ask how treatment fits into daily life and identify the specific point where access or use breaks down. The intervention should match the barrier: counseling alone cannot replace medication coverage, and a reminder cannot solve an intolerable adverse effect.
Apply it
A patient reports missed antiretroviral doses after losing insurance but describes a workable daily routine. Coordinate medication access and follow-up first, while checking for additional barriers, rather than assuming that a pill organizer will solve the principal problem.
Common pitfall: Detectable HIV RNA should trigger assessment, not a moral judgment. A standardized reminder plan can miss the actual cause and leave a correctable access problem untreated.
19.Which pregnancy findings change syphilis assessment?
Maternal syphilis assessment requires disease staging, review of prior treatment, serial nontreponemal titers, and evaluation of reinfection risk. A positive result should not be dismissed because a patient recalls unspecified treatment. CDC considers pregnant patients seropositive for syphilis infected unless adequate prior treatment and appropriate serologic response are clearly documented. Fetal risk exists across stages. Treatment decisions depend on stage and treatment history, while partner evaluation and ongoing risk assessment help prevent reinfection.
Apply it
A pregnant patient has reactive syphilis serology and remembers receiving an injection years earlier, but no records are available. Seek documentation, establish stage and current risk, and arrange appropriate treatment rather than assuming that the recalled injection proves adequate therapy.
Common pitfall: A vague treatment history cannot substitute for documented adequate therapy and serologic follow-up. Low titers also do not automatically eliminate fetal risk or the need for assessment.
20.When is candiduria a colonization finding?
Asymptomatic candiduria commonly reflects colonization, particularly with urinary devices or other predisposing factors. IDSA generally recommends removing correctable risk factors rather than prescribing antifungals. The specified high-risk exceptions are neutropenia, birth weight below 1,500 g, and planned urologic manipulation. Neutropenic patients and very-low-birth-weight infants require management consistent with invasive candidiasis recommendations; patients undergoing urologic manipulation need periprocedural antifungal treatment. Symptoms, obstruction, host status, and instrumentation plans distinguish these decisions from routine catheter-associated colonization.
Apply it
A stable, nonneutropenic catheterized adult has Candida in urine but no urinary symptoms, systemic illness, or planned urologic procedure. Review catheter necessity and remove it when feasible. A neutropenic patient, an infant weighing less than 1,500 g at birth, or a patient facing urologic manipulation requires a different treatment assessment.
Common pitfall: Treating every positive urine culture causes unnecessary exposure. Applying the usual no-treatment approach without checking neutropenia, birth weight, and urologic manipulation misses the specified exceptions.
IDSA Clinical Practice Guideline for the Management of Candidiasis
21.Which treatment is preferred for invasive ESBL infections?
IDSA recommends carbapenems for ESBL-producing Enterobacterales infections outside the urinary tract, including bloodstream and other invasive infections. Meropenem or imipenem-cilastatin is preferred over ertapenem in critical illness or hypoalbuminemia because patient physiology can make ertapenem exposure less reliable. Treatment selection also requires source control and susceptibility review. The practical distinction is between a stable patient suitable for a narrower logistical option and a critically ill patient whose pharmacokinetics and infection severity favor a different carbapenem.
Apply it
A critically ill adult with hypoalbuminemia develops ESBL Klebsiella bacteremia from a postoperative wound. Recommend meropenem or imipenem-cilastatin if susceptible, alongside surgical source control, instead of selecting ertapenem primarily for convenient once-daily administration during unstable illness.
Common pitfall: All carbapenems are not operationally interchangeable in every host. Convenience should not outweigh critical illness, altered protein binding, infection severity, or the need to drain infected material.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
22.Why can ceftriaxone fail against inducible AmpC producers?
Some Enterobacterales can increase AmpC production during exposure to susceptible beta-lactams, creating resistance after treatment begins. Enterobacter cloacae complex, Klebsiella aerogenes, and Citrobacter freundii are important moderate-risk examples. Cefepime is relatively stable against AmpC and has low induction potential, making it a suggested option when susceptibility and clinical circumstances support use. An initially susceptible ceftriaxone result should not automatically determine treatment of an invasive infection caused by one of these organisms.
Apply it
Blood cultures identify susceptible Enterobacter cloacae complex in a patient with a deep infection. Review the inducible AmpC risk and consider cefepime when appropriate rather than narrowing automatically to ceftriaxone based only on the initial susceptibility panel.
Common pitfall: Initial susceptibility is a snapshot, not a guarantee against resistance emerging during therapy. Avoid treating every organism historically grouped under an acronym as having identical AmpC risk.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
23.How does confirmed KPC production guide treatment?
For infections outside the urinary tract caused by KPC-producing Enterobacterales, IDSA identifies newer beta-lactam combinations with activity against KPC as preferred options, including meropenem-vaborbactam, ceftazidime-avibactam, and imipenem-cilastatin-relebactam. Choice still requires susceptibility, infection-site, patient, and prior-exposure assessment. Confirmed KPC production narrows the mechanism-based decision but does not eliminate the possibility of resistance to an individual agent. Avoid assuming that any carbapenem-resistant isolate requires a polymyxin-based regimen.
Apply it
A bloodstream isolate is confirmed KPC-producing K. pneumoniae and is susceptible to meropenem-vaborbactam. Assess this preferred mechanism-active option and patient-specific factors rather than defaulting to colistin simply because the organism is classified as carbapenem resistant.
Common pitfall: A resistance-category label is less useful than a mechanism plus agent-specific susceptibility. KPC-directed options should not be transferred unchanged to isolates producing metallo-beta-lactamases.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
24.Which treatments are preferred for invasive NDM-producing Enterobacterales infections?
IDSA 2026 guidance identifies aztreonam-avibactam and cefiderocol as preferred treatments for invasive NDM-producing Enterobacterales infections. Ceftazidime-avibactam plus aztreonam is an alternative when aztreonam-avibactam is unavailable. NDM spares aztreonam, but accompanying serine beta-lactamases can hydrolyze it; avibactam protects aztreonam from those enzymes without directly inhibiting NDM. The fixed combination coordinates drug and inhibitor exposure and simplifies administration. Confirm susceptibility because the mechanism alone does not guarantee activity.
Apply it
An NDM-producing Enterobacterales isolate causes bacteremia and also produces an ESBL. Assess susceptibility to aztreonam-avibactam and cefiderocol as preferred options. If aztreonam-avibactam is unavailable, consider ceftazidime-avibactam plus aztreonam using an appropriate combined administration and susceptibility-assessment strategy.
Common pitfall: Aztreonam alone may be destroyed by accompanying enzymes, while ceftazidime-avibactam alone remains vulnerable to NDM. The complementary mechanism does not make the alternative combination the preferred available product.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
25.Which urinary findings permit narrower resistant-organism therapy?
Uncomplicated cystitis differs from pyelonephritis, complicated urinary infection, and bacteremia in both tissue exposure requirements and treatment options. For resistant Enterobacterales, a susceptible oral agent may still be appropriate when the syndrome and patient factors support it. Conversely, a resistant organism does not automatically mandate the broadest intravenous drug. Establish whether fever, flank pain, obstruction, systemic instability, or bloodstream involvement changes the syndrome before choosing a bladder-focused agent or considering oral step-down.
Apply it
A stable patient has dysuria and frequency without fever, flank pain, obstruction, or bacteremia. The resistant E. coli isolate remains susceptible to an appropriate cystitis agent. Match treatment to the lower-tract syndrome instead of escalating solely because ESBL production is reported.
Common pitfall: The resistance label should not erase syndrome distinctions. However, calling an infection cystitis despite fever or bacteremia can lead to a drug with inadequate tissue exposure.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
26.How should difficult-to-treat Pseudomonas therapy be selected?
For nonurinary DTR Pseudomonas aeruginosa infections, preferred active options include ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-cilastatin-relebactam. IDSA 2026 guidance favors ceftolozane-tazobactam for DTR Pseudomonas pneumonia, informed by comparative observational outcomes and pulmonary exposure considerations. Cefiderocol has an alternative role. Demonstrate agent-specific susceptibility; activity cannot be inferred across these drugs. Once an active beta-lactam is established, routine continued combination therapy generally adds toxicity without established benefit.
Apply it
A patient has DTR Pseudomonas pneumonia, and the isolate is susceptible to ceftolozane-tazobactam and ceftazidime-avibactam. Favor ceftolozane-tazobactam when patient factors permit, optimize administration, and reassess the need for an aminoglycoside started empirically. Cefiderocol is an alternative rather than an interchangeable first choice.
Common pitfall: A shared antipseudomonal label does not establish cross-susceptibility or equivalent pneumonia evidence. The pneumonia preference remains conditional on demonstrated activity and patient suitability.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
27.What is preferred initial therapy for candidemia?
An echinocandin is recommended initial therapy for most nonneutropenic adults with candidemia. Fluconazole is an alternative for selected patients who are not critically ill and are unlikely to harbor a resistant species. Initial selection considers illness severity, prior antifungal exposure, species, susceptibility, and potential deep foci. Bloodstream Candida should prompt treatment and source evaluation rather than dismissal as contamination. Subsequent improvement can permit narrowing, but stability and microbiologic clearance must be demonstrated.
Apply it
A critically ill adult has blood cultures growing Candida before species identification. Begin an echinocandin while obtaining susceptibility information, following blood cultures, and evaluating the source, rather than waiting for full identification or assuming fluconazole susceptibility.
Common pitfall: Fluconazole can be appropriate in selected circumstances, but that does not make it the default for an unstable patient with unknown species and susceptibility.
IDSA Clinical Practice Guideline for the Management of Candidiasis
28.When can candidemia treatment step down to fluconazole?
Step-down from an echinocandin to fluconazole generally requires clinical stability, an isolate susceptible to fluconazole, and negative repeat blood cultures. These conditions combine host response, organism activity, and evidence that bloodstream infection has cleared. The ability to swallow is necessary for oral administration but is not sufficient for safe narrowing. Species-specific susceptibility matters, and deep or metastatic infection may alter the treatment plan. Step-down is a structured reassessment rather than an automatic calendar event.
Apply it
A patient with candidemia is stable, repeat cultures are negative, and the isolate is fluconazole susceptible. Assess oral absorption and interacting drugs, then consider step-down. If repeat cultures remain positive, investigate persistence instead of narrowing solely because several treatment days have elapsed.
Common pitfall: A fixed number of echinocandin days does not replace clinical stability and culture clearance. Oral tolerance alone cannot compensate for resistance or an uncontrolled source.
IDSA Clinical Practice Guideline for the Management of Candidiasis
29.How do high bacterial burden and limited source control change AmpC decisions?
Serratia marcescens, Morganella morganii, and Providencia species have a lower risk of clinically significant AmpC overexpression than Enterobacter cloacae complex, so susceptibility-guided therapy is generally reasonable. Endocarditis and CNS infections create a distinct concern because bacterial burden can be high and source control limited. IDSA considers cefepime instead of ceftriaxone reasonable in those circumstances even when ceftriaxone tests susceptible. This is a site- and burden-dependent decision rather than a rule that all these organisms require a carbapenem.
Apply it
A ceftriaxone-susceptible Serratia isolate causes endocarditis with limited source control. Consider active cefepime rather than applying the usual lower-AmpC-risk approach without accounting for the endovascular focus. A CNS infection raises a similar burden-and-source-control concern and also requires a site-appropriate regimen.
Common pitfall: Low species-level risk does not remove the importance of infection site. Conversely, the endocarditis or CNS exception should not become a blanket ceftriaxone prohibition for every Serratia infection.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
30.How does Candida osteomyelitis change treatment expectations?
IDSA recommends fluconazole for 6–12 months for susceptible Candida osteomyelitis, or an echinocandin for at least two weeks followed by fluconazole for 6–12 months. Selected cases require surgical debridement. Symptoms and imaging are not organism-specific, and mixed bacterial infection, especially with Staphylococcus aureus, can occur; biopsy and culture therefore matter. Established bone involvement requires a site-specific plan rather than a short uncomplicated-candidemia course.
Apply it
A patient with prior candidemia develops persistent vertebral pain and a biopsy grows susceptible Candida. Plan the recommended 6–12-month fluconazole course or an initial echinocandin sequence lasting at least two weeks before fluconazole transition, and assess debridement indications and possible bacterial coinfection.
Common pitfall: A previous bloodstream course does not establish adequate treatment of bone infection. A history of candidemia also should not replace tissue diagnosis when feasible.
IDSA Clinical Practice Guideline for the Management of Candidiasis
31.Why is an echinocandin not routine initial CNS candidiasis therapy?
Drug activity in blood does not ensure adequate activity in the central nervous system. For CNS candidiasis, IDSA recommends initial liposomal amphotericin B with or without flucytosine, followed by fluconazole after response when appropriate. Echinocandins are not recommended as routine treatment because CNS exposure and supporting evidence are inadequate. Infected CNS devices should be removed when possible. The infection site therefore overrides a simple extension of the usual candidemia-first echinocandin approach.
Apply it
Candida is recovered from cerebrospinal fluid in a patient with an infected neurosurgical device. Select a CNS-directed regimen and evaluate device removal rather than continuing an echinocandin solely because it is a standard initial choice for bloodstream Candida infection.
Common pitfall: A susceptible organism and a familiar first-line bloodstream drug do not guarantee CNS effectiveness. Site penetration and infected hardware must be addressed together.
IDSA Clinical Practice Guideline for the Management of Candidiasis
32.When does abdominal Candida require treatment and drainage?
Candida from a normally sterile operative abdominal specimen or a drain placed within 24 hours supports intra-abdominal candidiasis when clinical infection is present. Specimens from drains present longer than 24 hours are not useful for this diagnostic purpose because colonization undermines interpretation. Treatment combines an appropriate antifungal with drainage or debridement when indicated. Duration depends on clinical response and adequate source control. Specimen timing, provenance, and evidence of infection are all required.
Apply it
A patient with an anastomotic leak has sepsis and Candida recovered from an operative specimen or a drain placed 12 hours earlier. Treat the invasive infection and secure drainage. A Candida result from a drain present for five days cannot establish the same diagnosis by itself.
Common pitfall: Calling a drain specimen fresh without knowing when the drain was placed misses the operational distinction. A specimen from a longstanding drain is not equivalent to a normally sterile operative sample.
IDSA Clinical Practice Guideline for the Management of Candidiasis
33.When should asymptomatic bacteriuria be treated?
Asymptomatic bacteriuria is bacteriuria without symptoms attributable to urinary infection; pyuria does not convert it into symptomatic disease. IDSA recommends screening and treatment during pregnancy and before selected endoscopic urologic procedures involving mucosal trauma. Many other groups, including older adults and patients with diabetes, should not receive treatment solely for a positive culture. Establish symptoms and the relevant exception before prescribing. Treating colonization can cause adverse effects and promote resistance without improving patient outcomes.
Apply it
An older adult with diabetes has pyuria and a positive urine culture but no urinary symptoms, fever, or instability. Do not prescribe solely for those results. A separate patient undergoing an endourologic procedure with mucosal trauma requires a different assessment.
Common pitfall: Pyuria is not a treatment indication by itself. Conversely, the general recommendation against treatment should not obscure the pregnancy and qualifying urologic-procedure exceptions.
IDSA Guideline for the Management of Asymptomatic Bacteriuria
34.What determines initial antibacterial coverage in high-risk febrile neutropenia?
High-risk febrile neutropenia requires prompt inpatient intravenous treatment. The [IDSA fever-and-neutropenia guideline](https://www.idsociety.org/practice-guideline/neutropenic-patients-with-cancer/) supports an antipseudomonal beta-lactam such as cefepime, piperacillin-tazobactam, meropenem, or imipenem-cilastatin. Prior resistant isolates and local epidemiology can require different coverage. Vancomycin is not routine; indications include suspected catheter or skin infection, pneumonia, or hemodynamic instability. Persistent fever alone in an otherwise stable patient does not justify indiscriminate antibacterial additions.
Apply it
A patient with anticipated prolonged profound neutropenia develops fever without shock, pneumonia, a catheter-infection syndrome, or prior resistant-organism findings. Start an appropriate antipseudomonal beta-lactam promptly and obtain indicated cultures without delaying treatment. Add vancomycin when a specific clinical indication emerges.
Common pitfall: Vancomycin alone leaves major Gram-negative threats untreated. Routine addition for every fever also exposes patients without addressing a demonstrated gap; instability or a new focus requires a different reassessment.
SHEA/IDSA Guideline for Implementing an Antibiotic Stewardship Program · IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
35.How is penicillin allergy managed in pregnant patients with syphilis?
Penicillin G is the only known effective antimicrobial for treating fetal infection and preventing congenital syphilis. A pregnant patient with a true penicillin allergy should undergo desensitization and receive penicillin appropriate to the disease stage. Alternative agents should not be assumed to provide equivalent fetal protection. Assessment of the allergy history is useful, but a verified immediate allergy changes how penicillin is delivered rather than removing its role. Treatment access and timely coordination are essential.
Apply it
A pregnant patient with newly diagnosed syphilis has documented immediate penicillin hypersensitivity. Coordinate desensitization in an appropriate setting followed by stage-appropriate penicillin therapy, rather than substituting doxycycline or assuming that an alternative adult regimen also protects the fetus.
Common pitfall: Effective treatment for a nonpregnant adult cannot automatically be transferred to pregnancy. Desensitization is a treatment-enabling procedure, not proof that the allergy label was false.
36.What is preferred treatment for moderate-to-severe HIV-associated PCP?
NIH recommends trimethoprim-sulfamethoxazole as preferred therapy for Pneumocystis pneumonia, with intravenous administration for moderate-to-severe disease and transition to oral treatment after improvement when feasible. Treatment selection must account for disease severity, renal function, tolerability, and prior reactions. Alternative regimens have specific limitations and monitoring requirements. Severe hypoxemia also triggers a separate assessment for adjunctive corticosteroids. Recognizing Pneumocystis as a fungus does not make routine candidemia therapy an appropriate substitute.
Apply it
An adult with HIV has confirmed PCP, substantial hypoxemia, and no contraindication to TMP-SMX. Recommend intravenous TMP-SMX, assess eligibility for adjunctive corticosteroids, and plan monitoring rather than choosing fluconazole based solely on the organism's fungal classification.
Common pitfall: Fungal classification does not predict response to standard antifungals. An alternative PCP regimen also should not be chosen without considering severity, prior reactions, and its specific safety requirements.
37.When are corticosteroids indicated for HIV-associated PCP?
For HIV-associated PCP, NIH recommends adjunctive corticosteroids when room-air PaO2 is below 70 mmHg or the alveolar-arterial oxygen gradient is at least 35 mmHg. These criteria identify clinically important gas-exchange impairment. Corticosteroids should begin as soon as possible and within 72 hours after starting PCP therapy. They supplement effective antimicrobial treatment rather than replace it. These specific evidence-based criteria should not be transferred automatically to every non-HIV immunocompromised patient with PCP.
Apply it
A patient with HIV-associated PCP has a room-air PaO2 of 66 mmHg when TMP-SMX is started. Recommend prompt adjunctive corticosteroids because the oxygenation criterion is met, rather than waiting for respiratory failure or using CD4 count as the deciding threshold.
Common pitfall: A low CD4 count identifies vulnerability but is not the adjunctive-steroid threshold. The room-air oxygenation measurement and timing of effective PCP treatment are the decisive details.
38.Why check G6PD before selected PCP alternatives?
Primaquine and dapsone can cause hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency because vulnerable red cells cannot adequately handle oxidative stress. NIH recommends checking G6PD activity before using these drugs and choosing another agent if deficiency is present. They also have methemoglobinemia concerns that can complicate respiratory assessment. A plan to switch away from TMP-SMX therefore requires regimen-specific safety evaluation rather than simply selecting another drug listed as active against Pneumocystis.
Apply it
A patient with PCP cannot continue TMP-SMX, and clindamycin-primaquine is being considered. Obtain G6PD testing before primaquine and select another suitable regimen if deficient, while recognizing that unexplained oxygenation changes may also require evaluation for methemoglobinemia.
Common pitfall: An alternative regimen is not automatically safer for every patient. Prior tolerance of unrelated antibiotics provides no reassurance against G6PD-associated oxidative hemolysis.
39.How do polyvalent cations interfere with dolutegravir?
Dolutegravir can bind polyvalent cations in the gastrointestinal tract, reducing absorption through chelation. Magnesium- or aluminum-containing antacids therefore require dose separation according to prescribing instructions: dolutegravir is taken at least two hours before or six hours after these products. Calcium and iron supplements have a food-dependent exception and may be taken simultaneously with dolutegravir when taken with food. Product identity and meal timing distinguish correct counseling from an unnecessarily broad or unsafe instruction.
Apply it
A patient takes dolutegravir with a magnesium-aluminum antacid every morning. Move dolutegravir to at least two hours before or six hours after the antacid, and review other supplements rather than assuming all nonprescription products are irrelevant to antiretroviral exposure.
Common pitfall: Do not apply the calcium-and-iron food exception to magnesium-aluminum antacids. Conversely, instructing every patient to stop needed mineral supplementation can create an avoidable adherence barrier.
DailyMed: TIVICAY — Dolutegravir Sodium Prescribing Information
40.Why can dolutegravir raise creatinine without lowering filtration?
Dolutegravir inhibits renal transporters involved in tubular creatinine secretion, including OCT2 and MATE1. Serum creatinine may therefore increase modestly without a corresponding reduction in glomerular filtration. An early stable change after initiation, without other kidney-injury findings, supports this mechanism. Interpretation still requires the clinical context: progressive creatinine increases, oliguria, hemodynamic instability, or other abnormalities warrant evaluation for genuine renal dysfunction. The mechanism explains a pattern; it does not exclude every competing cause.
Apply it
Shortly after dolutegravir initiation, a stable patient's creatinine rises modestly and then plateaus, with no other renal abnormalities. Consider transporter-mediated reduced secretion while reviewing other causes, rather than automatically labeling the change as nephrotoxicity requiring antiretroviral discontinuation.
Common pitfall: Creatinine is affected by secretion as well as filtration. However, attributing a progressive or clinically concerning renal change to dolutegravir without evaluation can miss genuine kidney injury.
DailyMed: TIVICAY — Dolutegravir Sodium Prescribing Information
41.How is uncomplicated candidemia treatment duration anchored?
For nonneutropenic candidemia without metastatic complications, IDSA recommends at least two weeks after documented bloodstream clearance and resolution of attributable symptoms. Daily or every-other-day follow-up blood cultures establish clearance. In neutropenic patients, the minimum two-week post-clearance course also requires resolution of neutropenia and attributable symptoms; clearance and symptomatic improvement alone do not justify stopping while neutropenia persists. Deep foci require a separate site-specific duration.
Apply it
A nonneutropenic patient's therapy starts Monday, but cultures first become negative Thursday. With symptom resolution and no metastatic complications, anchor the minimum course to Thursday. If the patient remains neutropenic at the proposed stop date, reassess continuation rather than applying the nonneutropenic example unchanged.
Common pitfall: The first dose is not the clearance date. Documented clearance also does not remove the neutropenia-resolution requirement or the need to identify metastatic infection.
IDSA Clinical Practice Guideline for the Management of Candidiasis
42.What follow-up makes treatment of Staphylococcus aureus bacteremia assessable?
S. aureus bacteremia management requires appropriate active therapy and follow-up blood cultures rather than reliance on defervescence alone. Follow-up cultures establish whether bloodstream infection has cleared and identify persistence that requires renewed source assessment. The SHEA/IDSA stewardship guideline describes S. aureus bacteremia bundles that improve both appropriate treatment and follow-up culture performance. Laboratory notification must therefore trigger clinical action, and subsequent culture results need an identified reviewer.
Apply it
A patient with S. aureus bacteremia becomes afebrile, but no follow-up cultures have been obtained. Verify that treatment matches susceptibility, obtain follow-up cultures, and review the source rather than treating clinical improvement as proof of clearance. Persistent positivity should prompt reassessment rather than an automatic discharge plan.
Common pitfall: A favorable temperature trend does not establish microbiologic clearance. An electronic blood-culture alert is useful only when it produces timely treatment review and follow-up.
SHEA/IDSA Guideline for Implementing an Antibiotic Stewardship Program
43.Why can prolonged beta-lactam infusion improve exposure?
Beta-lactam activity is associated with the time that free drug concentrations remain above the organism's MIC. Extending an infusion can improve this exposure measure without treating peak concentration as the principal target. IDSA uses optimized prolonged-infusion strategies in selected resistant Gram-negative treatment recommendations. The approach still requires an active drug, an appropriate regimen, compatible preparation, and reliable delivery. Infusion optimization cannot overcome every resistance mechanism or substitute for susceptibility, renal assessment, and source control.
Apply it
An isolate remains susceptible to a beta-lactam for which the recommended resistant-organism regimen uses prolonged infusion. Verify the intended administration time and delivery feasibility, rather than allowing a default short infusion to undermine the exposure strategy selected by the clinical team.
Common pitfall: Longer infusion is an exposure tool, not a way to make any resistant isolate treatable. Renal function, regimen selection, stability, and actual administration remain essential.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
44.When is oral step-down reasonable after resistant Gram-negative bacteremia?
IDSA supports considering oral step-down when an appropriate oral agent is susceptible, the patient is hemodynamically stable, source control is adequate, and intestinal absorption is reliable. For ESBL bloodstream infections, trimethoprim-sulfamethoxazole or a fluoroquinolone may be options when these conditions are met. Agents with inadequate serum concentrations, such as nitrofurantoin or oral fosfomycin, are unsuitable substitutes. Route selection should follow evidence and exposure, rather than assuming that every resistant infection requires intravenous treatment throughout.
Apply it
A stable patient with controlled urinary-source ESBL bacteremia can absorb oral medication and has a susceptible TMP-SMX isolate. Evaluate oral step-down and individual safety factors instead of arranging intravenous access automatically or selecting nitrofurantoin because it treats lower urinary infection.
Common pitfall: Oral tolerance is only one condition for step-down. Susceptibility, systemic exposure, source control, stability, and absorption must align before an oral regimen becomes appropriate.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
45.What makes an OPAT monitoring plan operational?
OPAT requires serial laboratory monitoring tailored to the antimicrobial and patient, but ordering tests is only the first step. Results must reach a responsible clinician who reviews them and acts on abnormalities. The plan should specify tests, timing, reporting routes, clinical follow-up, and escalation contacts. IDSA does not support a universal identical test schedule for every drug. Drug-specific toxicity, renal trajectory, treatment duration, and prior abnormalities determine how intensive monitoring needs to be.
Apply it
A patient is discharged on OPAT with laboratory orders but no receiving clinician identified. Complete the review and escalation pathway before discharge, including who receives results and how urgent abnormalities are handled, rather than counting the existence of orders as adequate monitoring.
Common pitfall: A laboratory draw without result review is an incomplete safety process. A standard weekly panel also may be insufficient when renal function or toxicity risk is changing.
46.How is readiness for home antimicrobial treatment established?
Home OPAT suitability depends on more than medical stability. The patient or caregiver must be able to manage administration and vascular access safely, with a suitable environment, required supplies, communication, and follow-up. Assessment should identify practical barriers rather than assume ability from willingness alone. The care team must also confirm that parenteral treatment is still necessary. Demonstrated skills and a workable support plan connect the prescribed regimen to reliable treatment outside the hospital.
Apply it
A stable patient wants home OPAT but cannot demonstrate line care and has no available caregiver. Arrange training, reassess the delivery model, and consider other appropriate treatment options instead of equating discharge enthusiasm with safe independent administration.
Common pitfall: Clinical improvement does not establish home-treatment competence. Conversely, a practical barrier should prompt a tailored support plan rather than an unsupported judgment about the patient's motivation.
47.How does teach-back verify treatment understanding?
Teach-back asks the patient to explain the plan in their own words or demonstrate a skill, allowing the clinician to assess how clearly the information was communicated. It is more informative than asking whether the patient understands. Use plain language, focus on essential actions, and explain again when gaps appear before repeating the assessment. For antimicrobial treatment, useful targets include administration, interaction timing, missed-dose instructions, and symptoms that require contacting the team.
Apply it
After counseling about dolutegravir and antacid separation, ask the patient to describe tomorrow's medication schedule. If the doses still overlap, revise the explanation and ask again rather than accepting a polite statement that the instructions were understood.
Common pitfall: Teach-back is not a test of intelligence or a request to repeat jargon verbatim. Frame it as a check on the clarity of your explanation.
57.Which travel advice follows from Strongyloides transmission?
Infective Strongyloides larvae in contaminated soil penetrate exposed skin. Travel counseling should therefore connect exposure reduction with the route of entry: footwear and barriers that prevent direct skin contact with potentially contaminated soil address this risk. Food precautions alone do not address skin penetration. Ask about destination, activities, sanitation, and anticipated barefoot contact. After travel, retain the exposure history because autoinfection can sustain an acquired infection long after return.
Apply it
A traveler plans agricultural work in an endemic region and expects frequent barefoot soil contact. Explain skin penetration and recommend footwear and avoidance of direct contact with potentially fecally contaminated soil. Document the exposure for future assessment, especially before immunosuppression.
Common pitfall: Prevention advice must match the organism's transmission route. Returning home does not eliminate an infection already acquired, and later absence of eosinophilia cannot reliably exclude severe strongyloidiasis.
CDC DPDx: Strongyloidiasis · CDC: Clinical Overview of Strongyloides
Professional Practice22%
48.Which seven elements support a hospital stewardship program?
CDC's hospital core elements are leadership commitment, accountability, pharmacy expertise, action, tracking, reporting, and education. They connect resources and responsibility with interventions and measurable follow-through. A program cannot rely on education alone if no leader is accountable or prescribing data are unavailable. Assessing the elements helps identify why an intervention is failing operationally. The elements form a program framework, while specific interventions must be adapted to local resources, patient populations, and prescribing problems.
Apply it
A hospital distributes antibiotic newsletters but has no designated program leader or prescribing reports. Identify accountability, leadership support, tracking, and reporting gaps before adding more educational materials, and link the next intervention to a clearly assigned owner and measurable outcome.
Common pitfall: An educational campaign is one component rather than a complete stewardship program. Listing the core elements without assigning people, resources, and actions does not establish implementation.
CDC: Core Elements of Hospital Antibiotic Stewardship Programs
49.How do prospective audit and preauthorization differ?
Preauthorization requires approval before specified antimicrobials are used, whereas prospective audit and feedback reviews prescribing after treatment has begun and communicates recommendations. Both are core stewardship strategies with different workflow demands. Audit can incorporate new culture results and clinical evolution; preauthorization can influence the initial choice. Local coverage and response time matter because restrictions should not create unsafe delays. A scheduled review without feedback to the treating team is not a complete audit-and-feedback intervention.
Apply it
A pharmacist reviews broad-spectrum treatment after cultures return and recommends narrowing directly to the prescriber. Classify this as prospective audit and feedback. Requiring approval before the first restricted dose would instead be preauthorization and needs a reliable approval pathway.
Common pitfall: A formulary restriction and a postprescription review are not interchangeable labels. Either strategy can fail if staffing and communication do not support timely clinical decisions.
SHEA/IDSA Guideline for Implementing an Antibiotic Stewardship Program · The Core Elements of Hospital Antibiotic Stewardship Programs
50.How are antimicrobial days counted?
An antimicrobial day counts a patient receiving a particular antimicrobial on a calendar day, regardless of how many doses of that agent are administered that day. Different agents contribute separate days even when given on the same date. This measures exposure rather than dose size or treatment-course length. NHSN reporting also uses location and administration rules that must be followed consistently. Distinguish agent-specific antimicrobial days from the number of calendar days on any antimicrobial.
Apply it
A patient receives cefepime on four calendar days and vancomycin on three of those days. The combined agent-specific total is seven antimicrobial days, while the elapsed period on at least one antimicrobial is four calendar days.
Common pitfall: Counting doses inflates antimicrobial days, while counting only calendar days underestimates exposure to combinations. A summed DOT value is not the same measure as treatment duration.
51.What does the standardized antimicrobial administration ratio mean?
The SAAR compares observed antimicrobial days with days predicted by an NHSN statistical model for a defined antimicrobial category and location grouping. A value above one indicates use above the model prediction; below one indicates lower use. It does not directly measure appropriateness, resistance, or patient-level quality. A high value is a signal for investigation using local diagnoses, patient mix, prescribing practices, and outcomes. The denominator is model-predicted use rather than a universal recommended prescribing target.
Apply it
A unit records 900 observed antimicrobial days against 750 predicted days, giving a SAAR of 1.2. Review the clinical drivers and prescribing patterns before setting an intervention, rather than claiming that exactly 20% of treatment was unnecessary.
Common pitfall: A ratio above one does not prove overuse, and below one does not prove excellent care. Prediction models support screening rather than replace clinical appropriateness review.
52.When does a stratified antibiogram improve empiric selection?
An overall hospital antibiogram can obscure differences by location, population, or specimen source. The SHEA/IDSA guideline cites at least 30 isolates per organism as the benchmark for the relevant cumulative or stratified summary. Even with that minimum, highly selected subgroups can produce unstable or biased estimates. An antibiogram estimates the probability of empiric activity; the patient's prior cultures and current susceptibility results provide more specific evidence.
Apply it
Before publishing an ICU-specific Pseudomonas summary, verify that at least 30 qualifying isolates support the organism-level estimate and assess representativeness. If counts are smaller, avoid presenting the subgroup percentage as a stable basis for empiric policy.
Common pitfall: Thirty isolates is a minimum benchmark rather than a guarantee of precision or freedom from bias. Selective testing and suppressed susceptibility results can distort the summary.
SHEA/IDSA Guideline for Implementing an Antibiotic Stewardship Program
53.How should carbapenemase results support resistance tracking?
Resistance surveillance is more informative when it distinguishes mechanisms rather than combining every carbapenem-resistant isolate into one category. KPC and metallo-beta-lactamases imply different treatment options, and changes in their local distribution can affect empiric pathways and formulary needs. Pair mechanism information with organism, location, infection versus colonization status, and susceptibility trends. A surveillance signal should prompt verification and targeted review rather than an assumption that every detected resistant organism represents a new clinical infection.
Apply it
A hospital previously dominated by KPC detects several NDM-producing isolates. Review laboratory confirmation, affected units, infection prevention implications, and treatment pathways rather than updating only the overall carbapenem-resistance percentage and leaving mechanism-specific guidance unchanged.
Common pitfall: Combining mechanisms can hide a clinically important shift despite a stable overall resistance rate. Colonization surveillance results also should not be counted automatically as treated infections.
IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections · SHEA/IDSA Guideline for Implementing an Antibiotic Stewardship Program
54.Which measures interrupt C. difficile transmission?
C. difficile infection prevention combines prompt recognition, contact precautions, appropriate patient placement, dedicated equipment when possible, and environmental cleaning with an effective sporicidal product. Spores make ordinary assumptions about surface disinfection inadequate. Diagnostic stewardship and antibiotic stewardship complement these measures by limiting misclassification and avoidable antibiotic exposure. A patient with suspected clinically significant infection may need precautions while evaluation proceeds. A positive test alone still requires clinical interpretation and should not replace symptom-based assessment.
Apply it
A hospitalized patient develops unexplained clinically significant diarrhea after antibiotics. Implement appropriate precautions during assessment and ensure sporicidal environmental cleaning rather than waiting for a result before considering transmission or assuming routine cleaning alone addresses spores.
Common pitfall: Antibiotic treatment does not replace infection prevention. Repeated testing or a test of cure also should not be used as a shortcut for assessing symptoms and precautions.
Clinical Guidance for C. diff Infection Prevention in Acute Care Facilities · C. diff: Facts for Clinicians
55.How should mechanism-active antibiotics be evaluated for the formulary?
Formulary evaluation should connect local clinical need with comparative evidence, resistance mechanisms, safety, administration, monitoring, and cost. Two newer agents are not interchangeable merely because both target resistant Gram-negative organisms. Local KPC, metallo-beta-lactamase, and Pseudomonas patterns can create different priorities. Stewardship criteria should preserve timely access when an agent is indicated and support reassessment after susceptibility results. Acquisition price alone does not capture toxicity, treatment failure, or the operational requirements of safe use.
Apply it
A committee compares two newer beta-lactam combinations. Map their activity to local resistance mechanisms and relevant infection syndromes, then design access and review criteria rather than selecting the cheaper product on the assumption that both cover all carbapenem-resistant organisms equally.
Common pitfall: Broad marketing categories do not establish equivalent spectra. Restriction criteria that are disconnected from laboratory turnaround and approval coverage can delay an otherwise appropriate treatment choice.
SHEA/IDSA Guideline for Implementing an Antibiotic Stewardship Program · IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
56.How can an HBV screening program connect results with vaccination?
A prevention program should route each HBV triple-panel pattern to a defined action. An entirely negative panel in someone without documentation of a completed vaccine series supports susceptibility and offering hepatitis B vaccination according to ACIP recommendations. HBsAg positivity requires linkage to HBV care, while resolved infection requires reactivation-risk counseling. Previously vaccinated responders can have waning anti-HBs, so a negative surface antibody alone should not trigger indiscriminate revaccination. Program measures should track completed actions as well as tests ordered.
Apply it
A clinic implements one-time adult HBV screening. Build result pathways for vaccine initiation and completion, infection-care referral, and reactivation counseling. For an unvaccinated adult with an entirely negative panel, arrange vaccination rather than merely documenting a negative test.
Common pitfall: Counting screening tests alone misses whether prevention occurred. An anti-HBs result without vaccination history and the remaining panel cannot reliably assign every patient to revaccination.
58.Which balancing measures make stewardship improvement credible?
A stewardship intervention should measure both the intended prescribing change and possible unintended clinical consequences. Reduced antibiotic use is informative, but safety assessment may include treatment failure, mortality, readmission, or other locally relevant outcomes. Process measures show whether the intervention occurred; outcome measures show what followed. Interpretation should consider patient mix and concurrent changes. A favorable utilization trend alone does not establish that an intervention improved care, especially if patients received inadequate or delayed treatment.
Apply it
A hospital reduces broad-spectrum use after introducing review rounds. Track recommendation uptake and clinical outcomes alongside utilization, and examine any rise in infection-related readmissions before declaring success based solely on fewer antimicrobial days.
Common pitfall: Lower consumption is not automatically better treatment. A before-and-after improvement also cannot establish causation when case mix, diagnostic practices, or other interventions changed simultaneously.
SHEA/IDSA Guideline for Implementing an Antibiotic Stewardship Program
59.How can clinical decision support improve antibiotic review?
Useful decision support delivers actionable information at a point where the clinician can change care. Examples include prompting review when culture results return, linking prescribing to an indication, and making duration or reassessment plans visible. Design should fit workflow and prioritize clinically important signals to limit alert fatigue. An alert is a process tool rather than proof of appropriate treatment. Evaluate whether clinicians act on it and whether prescribing and safety outcomes improve.
Apply it
An alert fires repeatedly without showing culture results or offering a review action. Redesign it to present relevant microbiology and a practical reassessment step, then monitor uptake and consequences rather than measuring success by the number of alerts displayed.
Common pitfall: More alerts can increase burden without improving decisions. A technically functioning rule can still fail if it appears too late or lacks an actionable recommendation.
The Core Elements of Hospital Antibiotic Stewardship Programs
60.How do absolute and relative effects change evidence interpretation?
Relative effects describe proportional change, whereas absolute effects show how many events differ between groups. A large relative reduction can correspond to a small absolute benefit when baseline risk is low. For a beneficial intervention, number needed to treat is the reciprocal of absolute risk reduction expressed as a proportion, provided the endpoint and follow-up are specified. Evidence appraisal should also examine uncertainty, bias, and applicability. These calculations support interpretation but cannot repair an unreliable study design.
Apply it
In a hypothetical randomized study, an outcome occurs in 10% of controls and 6% of treated patients over the same follow-up. Calculate a four-percentage-point absolute reduction, a 40% relative reduction, and an NNT of 25 for that endpoint.
Common pitfall: A relative reduction without baseline risk can exaggerate perceived benefit. NNT also depends on the specified population, outcome, and follow-up rather than being a permanent drug property.
BCIDP Examination Specifications — Effective October 2025 · Chapter 15: Interpreting results and drawing conclusions | Cochrane
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Use the official 18%/60%/22% domain weights to organize study, while checking every subdomain against the complete BPS outline.
- Distinguish infection from colonization before choosing treatment: urine cultures, Candida screening, and C. difficile molecular results require clinical context.
- Connect resistance mechanisms to active agents, then check infection-site exposure, patient physiology, source control, and susceptibility.
- Practise initial HIV regimen selection, febrile-neutropenia coverage, bacterial bloodstream follow-up, HBV vaccination decisions, and transmission-specific travel counseling.
- Practise HBV serology, TB evaluation, vancomycin exposure calculations, PCP oxygenation criteria, DOT counting, and SAAR interpretation.
- Make implementation explicit: administration timing, interactions, result ownership, oral transition criteria, caregiver skills, and follow-up.
- Interpret stewardship metrics alongside clinical outcomes; distinguish a useful signal from proof of inappropriate prescribing.
A practical preparation plan
1. Map the full specialty scope
Build a study map from the October 2025 BPS outline. Mark the concepts covered here and separately identify remaining organ-system, special-population, vaccination, travel medicine, and practice-management topics requiring study.
2. Build mechanism-to-decision tables
Compare ESBL, inducible AmpC, KPC, and metallo-beta-lactamases by mechanism, useful treatment options, and misleading susceptibility assumptions. Add separate columns for bladder, bloodstream, pulmonary, and CNS exposure requirements.
3. Work through patient assessments
Interpret complete HBV panels, evaluate positive TB tests, assess adherence barriers, and distinguish symptomatic infection from colonization. For initial HIV therapy and febrile neutropenia, state which baseline findings change the regimen.
4. Calculate and explain
Solve exposure and utilization problems with units shown. Explain the assumptions behind AUC estimates, the difference between DOT and calendar duration, and why a SAAR cannot identify the percentage of unnecessary therapy.
5. Complete the implementation plan
For each treatment case, specify administration, monitoring, interaction management, source control, step-down criteria, and follow-up ownership. Include host-specific duration requirements. Use teach-back to turn a correct prescription into a workable patient plan.
6. Review errors against evidence
Complete the independent questions, classify each error by the official domain, and revisit the supporting primary source. Use flashcards for spaced recall, then test the same principle in a different clinical setting.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- Infectious Diseases Pharmacy
- Examination Content Outlines
- BCIDP Examination Specifications — Effective October 2025
- BCIDP 2024 Job Analysis Report
- BPS Candidate’s Guide
- IDSA 2026 Guidance on Antimicrobial Resistant Gram-Negative Infections
- Consensus Guideline for Therapeutic Monitoring of Vancomycin
- Clinical Testing and Diagnosis for Hepatitis B
- Clinical Testing and Diagnosis for Tuberculosis
- IDSA Clinical Practice Guideline for the Management of Candidiasis
- IDSA Guideline for the Management of Asymptomatic Bacteriuria
- IDSA Clinical Practice Guidelines for OPAT
- SHEA/IDSA Guideline for Implementing an Antibiotic Stewardship Program
- NIH: Adherence to the Continuum of Care
- CDC: Syphilis During Pregnancy
- NIH: Pneumocystis Pneumonia
- The Core Elements of Hospital Antibiotic Stewardship Programs
- CDC: Core Elements of Hospital Antibiotic Stewardship Programs
- NHSN FAQs: Antimicrobial Use
- C. diff: Facts for Clinicians
- Clinical Treatment of C. auris Infections
- Pneumocystis Pneumonia Basics
- Influenza Antiviral Medications: Summary for Clinicians
- NIH: Integrase Strand Transfer Inhibitor–Based Regimens
- NHSN FAQs: Antimicrobial Use Option Analysis
- AHRQ: Use the Teach-Back Method
- Clinical Guidance for C. diff Infection Prevention in Acute Care Facilities
- CDC DPDx: Strongyloidiasis
- CDC DPDx: Ascariasis
- CDC: Clinical Overview of Strongyloides
- Class II Special Controls Guideline Document: Toxin Gene Amplification Assays for the Detection of Clostridium difficile
- DailyMed: TIVICAY — Dolutegravir Sodium Prescribing Information
- NIH: Pneumocystis Pneumonia — Brief View
- Chapter 15: Interpreting results and drawing conclusions | Cochrane
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.